"Our hope is that if early detection [of brain cancer] is more feasible, then there is an increased chance of survival."
The average glioblastoma patient survives 12-18 months after diagnosis. The crux of the diagnostic is a biochip that uses electrokinetic technology to detect biomarkers, or active Epidermal Growth Factor Receptors (EGFRs), which are overexpressed in certain cancers such as glioblastoma and found in extracellular vesicles. “Extracellular vesicles or exosomes are unique nanoparticles secreted by cells. They are big—10 to 50 times bigger than a molecule—and they have a weak charge. Our technology was specifically designed for these nanoparticles, using their features to our advantage,” says Hsueh-Chia Chang, a professor of chemical and biomolecular engineering at the University of Notre Dame and lead author of the study about the diagnostic published in Communications Biology.
Continue Reading.












